Navigation Links
Metabolic Solutions Development Company Reports Positive Top-Line Results From Phase 2a Study of Its Second Compound to Treat Type 2 Diabetes
Date:9/8/2011

KALAMAZOO, Mich., Sept. 8, 2011 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) confirmed today the potential of MSDC-0602 to achieve significant glucose control in type 2 diabetes patients and increase insulin sensitivity based on preliminary analysis from its Phase 2a trial of MSDC-0602, a novel insulin sensitizer.

Importantly, given the blood glucose (HbA1c) lowering shown in this short study, these data support the company's expectation of a >1.5 percent reduction in HbA1c potentially without the undesirable weight gain and other PPAR-related side-effects(1). According to the Diabetes Control and Complications Trial, as HbA1c is lowered, the risks of diabetic complications such as eye, nerve and heart disease is significantly reduced.

"This proof-of-concept trial affirmed the potential of this novel insulin sensitizer to lower blood glucose and increase insulin sensitivity without the side-effects found with currently marketed products," said Jerry Colca, Ph.D., president and Chief Scientific Officer of MSDC. "The data are encouraging and we are proceeding to design a Phase 2b study of longer duration."  

The safety, tolerability and efficacy of MSDC-0602 were evaluated in a 28-day, randomized, double-blind, comparator- and placebo-controlled, multi-dose study in 129 patients with type 2 diabetes. Patients were randomized to MSDC-0602, 45 mg of pioglitazone or placebo. No safety concerns were uncovered for any treatments and all treatments were well tolerated.  This study follows the completion of two Phase 1 trials in which no safety concerns were observed. Additional safety and expanded efficacy data will be obtained from a Phase 2b study of MSDC-0602 that is targeted to begin in the first quarter of 2012.

MSDC-0602 is an insulin sensitizer that is selective for a molecular target connecting mitochondrial metabolism to cell function. Additionally, the compound's PPAR-independent pharmacology has not produced the side effects associated with activation of PPARγ.

Insulin sensitizing compounds exert important metabolic effects on mitochondrial metabolism that invoke a molecular switch that controls important cellular processes including sensitivity to insulin. MSDC has identified a novel molecular target through which its two lead insulin sensitizers, MSDC-0602 and MSDC-0160, work to treat type 2 diabetes. The compounds selectively modulate mitochondrial control of certain metabolic-signaling and nutrient-sensing pathways resulting in improved insulin action and generation of brown adipose tissue without fluid retention or weight gain.  

EASD Oral Presentation

There is an expectation there will be weight control over longer treatments with MSDC-0602 given the "browning" of adipose stores. Several recent studies(2,3) have shown that brown adipose tissue or BAT exists in some adult humans. BAT is brown in color because it has a high concentration of mitochondria. Unlike white adipose tissue, BAT is designed to burn rather than store fat. The amount of brown fat is inversely proportioned to body weight (and white adipose tissue). MSDC compounds favor the development of brown fat in animal models and human cells in tissue culture.

MSDC will present study results on the impact of its insulin sensitizing agents on the browning of progenitor cells from the axillary fat pad in a PPAR-independent manner at the upcoming 47th European Association for the Study of Diabetes Annual Meeting in Lisbon, Portugal on Monday, September 12 - 16, 2011:

New insulin sensitisers produce differentiation of brown-like adipose cells from a subcutaneous fat depot and increase secretion of adiponectin in vitro
W.G. McDonald et al, Oral Presentation 21 in Brown adipose tissue and mitochondria, Tuesday, September 13, 11:15 AM – 11:30 AM, Hispano Hall.

About Metabolic Solutions Development Company

Metabolic Solutions Development Company (www.msdrx.com) is a drug discovery and development company investigating novel molecular targets and new therapies for metabolic diseases associated with mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. The company has raised more than $55 million to support development of its lead compounds MSDC-0160 and MSDC-0602.

(1) http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm109136.htm
(2) Cypress AM, et al. NEJM. 2009 Apr 9; 360:1509-1517.
(3) Cannon B. and Nedergaard J. Physiol Rev. 2004. 84:277-359.


'/>"/>
SOURCE Metabolic Solutions Development Company, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
2. Study Uncovers Key Success Factors and Common Failure Points for Launching New Metabolic Products in Todays Competitive Healthcare Market
3. BioRestorative Therapies Signs License Agreement With University of Utah to Obtain Adipose (Fat) Tissue for its ThermoStem Program to Treat Obesity and Metabolic Disorders
4. Metabolic Solutions Development Company to Present Recent Findings on the Therapeutic Potential of Increasing Brown Fat in the Treatment of Diabetes at Annual American Diabetes Association Conference
5. GT Life Sciences Broadens Intellectual Property Portfolio with Issuance of U.S. Patent on Core Computational Systems and Methods for Genomic-based Metabolic Modeling
6. Creating a Road Map for Successful Metabolic New Product Launches
7. Cytotech Labs Unravels Hallmark Insight Into Metabolic Control of Cancer, Presents Work at Major AACR Cancer Meeting
8. Metabolic Solutions Development Company Launches Phase 2a Trial of Its Second Compound to Treat Type 2 Diabetes
9. Dave Anderson and William Thomsen Join SRI Internationals Center for Advanced Drug Research to Lead Programs in Proteomics and Metabolic Disease Drug Discovery
10. Bionovo Announces Publication Describing How Metabolic Adaptability Contributes to the Metastasis of Tumors
11. Metabolic Status Before Pregnancy Predicts Subsequent Gestational Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)...   Seno Medical Instruments, Inc. , the leader ... the development of an opto-acoustic (OA/US) imaging device, today ... SVP of Engineering. Mr. Miller previously served as the ... headquarters in Bothell, Washington . Mr. ... to the development of innovative medical imaging products that ...
(Date:1/18/2017)... 2017  Tarix Orphan LLC today announced that the ... Pediatric Disease (RPD) designation for the company,s drug candidate ... (RDEB), a rare genetic skin disorder. There are currently ... to supportive care. "The RPD designation for ... granted by the FDA in this indication," said ...
(Date:1/18/2017)... YORK , January 18, 2017 ... of people regarding the use of cannabis both for medical ... only are more Americans open to the use of cannabis, ... financial sectors. According to Arcview Market Research, the North American ... up 30% from the previous year. The research projects sales ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... 2017 , ... Floundering on New Year’s resolutions? Need an excuse to get ... reset. The U.S. Apple Association agrees and recommends starting each day with apples, ... to heart disease. , The U.S. Apple Association – which represents apple growers and ...
(Date:1/17/2017)... ... January 17, 2017 , ... In the crowded Ath-leisure market, ... stand-out company for several differences from other mainstream brands. , Firstly, in ... is called 'Agile' manufacturing - http://www.leanproduction.com/agile-manufacturing.html . It allows them to have ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... SunView Software’s ... Award for Innovation of the Year. , Each year, Pink Elephant recognizes ... an innovative approach to address a specific business problem or opportunity. The award highlights ...
(Date:1/17/2017)... Clemente, CA (PRWEB) , ... January 17, 2017 ... ... Diego County, as well as Palm Desert, is opening a new office in ... Brainsway deep transcranial magnetic stimulation (dTMS) in Southern California, successfully treating individuals struggling ...
(Date:1/17/2017)... New York (PRWEB) , ... January 17, 2017 ... ... network – SightMD – will lecture to primary eye care practitioners on the ... conditions at the upcoming 13th Semi-Annual Continuing Education Symposium, according to eye surgeon, ...
Breaking Medicine News(10 mins):